IGFBP-3 Blood Test Explained: What It Measures and Why It's Ordered

IGFBP-3 (insulin-like growth factor binding protein 3) is a circulating protein that binds and transports insulin-like growth factors in blood. A 2015 clinical review described IGFBP-3 as the most abundant of the IGF binding proteins in the circulation, carrying the majority of circulating IGF-I within a ternary complex that also contains the acid-labile subunit (PMID 26522455). This page summarises what the published literature says the IGFBP-3 test measures and why it appears on laboratory panels. This page is for educational purposes only and is not medical advice; consult a licensed physician about any laboratory result, symptom or treatment decision.

What IGFBP-3 is and where it comes from

Reviews of the growth hormone (GH)/IGF axis describe hepatic production as the dominant source of circulating IGFBP-3, with synthesis regulated in parallel with IGF-I under growth hormone control; a review of laboratory investigations in GH-related disorders described both IGF-I and IGFBP-3 as GH-dependent markers used to reflect integrated GH secretion (PMID 31939487). Because the ternary complex extends the half-life of IGF-I in blood, the 2015 review noted that IGFBP-3 concentrations in serum are far more stable across the day than pulsatile GH measurements (PMID 26522455).

IGFBP-3 is not only a carrier. A 2025 review of IGFBP-3 in human disease described the protein as acting through several distinct cell signalling pathways, including actions that do not depend on binding IGF-I (PMID 40213590). Researchers working in cell models have described such IGF-independent activity directly: one laboratory study reported that IGFBP-3 inhibited Wnt signalling in metastatic melanoma cells (PMID 27377812). That dual biology is one reason IGFBP-3 appears both as an endocrine marker and as a research analyte in other fields.

What the blood test actually measures

The test reports the total concentration of IGFBP-3 in serum or plasma, not the fraction bound to IGF-I and not tissue-level activity. A review of laboratory investigation in GH-related disorders emphasised that results are method-dependent and that age- and sex-specific reference intervals generated for the specific assay are required for meaningful comparison (PMID 31939487). The same review discussed the practical limitations of measuring GH axis analytes, including assay standardisation issues that make results from different platforms difficult to compare directly (PMID 31939487).

Why clinicians order an IGFBP-3 test

Evaluating suspected growth hormone deficiency

The best-established clinical use sits in paediatric and adult endocrinology. A review of the diagnosis of growth hormone deficiency described a diagnostic process combining auxology, clinical context and biochemical testing, in which IGF-I and IGFBP-3 serve as GH-dependent screening measurements used alongside GH stimulation testing rather than as stand-alone diagnostic tests (PMID 20523017). The review emphasised that no single biochemical test defines GH deficiency and that results must be read against the patient's growth pattern and clinical picture (PMID 20523017).

Characterising IGF deficiency states

A review of the spectrum of insulin-like growth factor deficiency described a continuum ranging from GH deficiency through GH insensitivity and primary IGF-I deficiency, in which measurement of IGF-I together with its binding proteins helps locate where along the axis the defect lies (PMID 23182818). In that framework, the pattern of IGF-I and IGFBP-3 relative to GH is more informative than either value in isolation (PMID 23182818).

Follow-up of GH excess and GH treatment

Laboratory review literature on GH-related disorders described IGF-axis markers as tools used in the follow-up of both GH deficiency and GH excess, where they reflect integrated GH exposure over time (PMID 31939487). The 2015 IGFBP-3 review similarly positioned the protein as a marker of GH status whose concentration tracks the GH/IGF-I axis (PMID 26522455).

Research and biomarker-discovery settings

Beyond endocrinology, IGF-axis proteins are measured in observational research. A 2020 proteomic study screened circulating proteins to identify candidate biomarkers of sleep apnea (PMID 32369590), and a 2022 study measured plasma growth-related cytokines in children with vasovagal syncope compared with controls (PMID 36312268). A prospective cohort study evaluated a panel of candidate angiogenesis-related circulating biomarkers in patients with laryngeal carcinoma (PMID 36939422). Measurements made in these research contexts are not the same as a clinically validated diagnostic test.

High and Low IGFBP-3 Values: What Studies Report

Lower-than-expected values

Because IGFBP-3 synthesis is GH-dependent, reviews of GH deficiency diagnosis described reduced IGF-I and IGFBP-3 as findings consistent with — though not proof of — impaired GH action (PMID 20523017). The IGF deficiency review noted that low values also occur in GH insensitivity and in primary IGF-I deficiency, where GH itself may be normal or elevated (PMID 23182818). Systemic illness is another context in which the axis shifts: a 2024 review of IGFBP-2 in critical illness examined binding proteins of the GH/IGF axis as prognostic markers in critically ill patients, describing the axis as substantially perturbed during severe illness (PMID 39585162).

Higher-than-expected values

Elevated GH-dependent markers are the expected pattern in states of GH excess, which is why review literature on GH-related disorders discusses these analytes in the diagnosis and monitoring of acromegaly as well as deficiency (PMID 31939487). High values are also reported in healthy people simply as a function of age and pubertal stage, which is why the 2015 review stressed interpretation against age-matched norms rather than a single cut-off (PMID 26522455).

Oncology and epidemiology

IGFBP-3 has been studied extensively in cancer epidemiology, with mixed and context-dependent results. A review of IGF-I, insulin and prostate cancer discussed circulating IGF-axis components, including binding proteins, in relation to prostate cancer risk (PMID 20126849). A 2020 review of vitamin D and the insulin-like growth factor system examined interactions between vitamin D status and IGF-system components, including IGFBP-3, with implications for colorectal neoplasia (PMID 32379895). Mechanistic work has described both growth-restraining and context-specific roles: the 2025 review summarised IGFBP-3 signalling across multiple human diseases and different pathways (PMID 40213590), and the melanoma cell study reported inhibition of Wnt signalling by IGFBP-3 (PMID 27377812). None of this research establishes IGFBP-3 as a cancer screening test.

Assay and interpretation caveats described in the literature

• Age and puberty dominate the range. Reference data must be age- and sex-specific, as described in reviews of GH-axis laboratory testing (PMID 31939487).
• Methods are not interchangeable. The same review highlighted assay standardisation as a recurring limitation when comparing results across laboratories (PMID 31939487).
• Nutrition and systemic illness alter the axis. Reviews of IGF deficiency described nutritional and systemic influences on IGF-axis markers independent of pituitary function (PMID 23182818), and critical illness research described broad perturbation of GH/IGF binding proteins (PMID 39585162).
• Total protein is not bioavailable IGF-I. The 2015 review described IGFBP-3 as a carrier within a ternary complex, so a concentration alone does not describe IGF-I bioactivity at tissue level (PMID 26522455).
• One value rarely decides anything. Reviews of GH deficiency diagnosis described IGFBP-3 as one input into a multi-step assessment that includes stimulation testing and growth data (PMID 20523017).

What this page does not do

It does not supply reference ranges, interpret an individual result, or suggest what any value means for a particular person. Published reviews consistently frame IGFBP-3 as a context-dependent marker whose meaning depends on age, assay, clinical presentation and companion tests (PMID 31939487, PMID 23182818). Questions about a specific laboratory report, including whether repeat or additional testing is appropriate, belong with the clinician who ordered it. This page is for educational purposes only and is not medical advice; consult a licensed physician for interpretation of any test result.

References

• Insulin-like growth factor binding-protein-3 (IGFBP-3) (Best Practice & Research Clinical Endocrinology & Metabolism, 2015)
• Laboratory investigations in the diagnosis and follow-up of GH-related disorders (Archives of Endocrinology and Metabolism, 2019)
• Diagnosis of growth hormone deficiency (Endocrine Development, 2010)
• Spectrum of insulin-like growth factor deficiency (Endocrine Development, 2012)
• Role of IGFBP-3 in Human Diseases Relying on Different Cell Signaling Pathways (Advanced Biomedical Research, 2025)
• IGFBP-3 inhibits Wnt signaling in metastatic melanoma cells (Molecular Carcinogenesis, 2017)
• IGFBP-2 in Critical Illness: A Prognostic Marker in the Growth Hormone/Insulin-like Growth Factor Axis (Pathophysiology, 2024)
• IGF-I, insulin and prostate cancer (Arquivos Brasileiros de Endocrinologia e Metabologia, 2009)
• Vitamin D and the insulin-like growth factor system: Implications for colorectal neoplasia (European Journal of Clinical Investigation, 2020)
• Proteomic biomarkers of sleep apnea (Sleep, 2020)
• Plasma human growth cytokines in children with vasovagal syncope (Frontiers in Cardiovascular Medicine, 2022)
• Candidate Angiogenesis-Related Biomarkers in Patients with Laryngeal Carcinoma (AngLaC): A Prospective Cohort Study (Otolaryngology–Head and Neck Surgery, 2023)